Clinical Trials Resource Center

Dental Filling

July 10, 2006

Acologix reported positive results of a phase II trial of AC-100, their novel synthetic peptide to promote dentin formation, at the Annual Meeting of the International Association for Dental Research (IADR) in Brisbane, Australia. Results from the study indicated that the drug was efficacious in stimulating the formation of new dentin when applied to tooth defects at 2 months. The greatest increase in dentin thickness was observed in the deepest cavities (remaining dentin thickness <0.5 mm). No serious adverse events were reported. This randomized, double-blind, placebo-controlled study enrolled 35 patients scheduled for third-molar (wisdom tooth) extraction, who each received 200 ug AC-100 on one tooth and placebo on another applied on days 0, 2 and 4 through dentin tubules.

Related Medical Areas

This information does not represent a Lupus Research Institute endorsement of any listed study. It is merely a notice that the study is available. If you are presently under the care of a physician for lupus or other conditions, you should not disrupt your current program without discussing it with your doctor(s). Do not contact the Lupus Research Institute for information on these studies. Only contact the listed numbers. The Lupus Research Institute does not have any jurisdiction over or further involvement with these studies, other than to make people aware that they are being conducted.